HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Synergistic effect of atorvastatin and Cyanidin-3-glucoside on angiotensin II-induced inflammation in vascular smooth muscle cells.

Abstract
Statins have often been used in atherosclerosis treatment because of its pleiotropic effects on inflammation. However, some adverse effects of high doses of statin show reverse effects after withdrawal. Cyanidin-3-glucoside (C3G) is a powerful anti-inflammation and antioxidant that has been of interest for use in combination with low doses of statin, which may be alternative treatment for atherosclerosis. The objective is to investigate the synergistic effect of atorvastatin and C3G in angiotensin II (Ang II)-induced inflammation in vascular smooth muscle cells. Human aortic smooth muscle cells (HASMCs) were exposed to Ang II with or without atorvastatin and C3G alone, or in combination. The results revealed that the combination of atorvastatin and C3G produces synergism against inflammation and oxidative stress. The mechanism of the combination of atorvastatin and C3G suppressed the translocation of the p65 subunit of NF-κB from cytosol to nucleus, and attenuated the expression of proteins including inducible nitric oxide synthase, intracellular adhesion molecule 1(ICAM-1), and vascular cell adhesion molecule 1(VCAM-1), in addition to nitric oxide (NO) production. Moreover, C3G exerts the antioxidative properties of atorvastatin through down-regulating NOX1 and promoting the activity of the Nrf2(-)ARE signaling pathway and downstream proteins including heme oxygenase (HO-1), NAD(P)H:quinoneoxidoreductase 1 (NQO-1), and glutamate-cysteine ligase catalytic subunit (γ-GCLC), besides increasing the activity of superoxide dismutase (SOD) enzymes. Taken together, these results suggest that a combination of low dose statins and C3G might serve as a potential regulator of the atherosclerosis process which is mediated by attenuating oxidative stress, thereby inhibiting NF-κB and activating Nrf2 signaling pathways induced by Ang II.
AuthorsRungusa Pantan, Jiraporn Tocharus, Apichart Suksamrarn, Chainarong Tocharus
JournalExperimental cell research (Exp Cell Res) Vol. 342 Issue 2 Pg. 104-12 (Mar 15 2016) ISSN: 1090-2422 [Electronic] United States
PMID26957227 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2016 Elsevier Inc. All rights reserved.
Chemical References
  • Anthocyanins
  • Anti-Inflammatory Agents
  • Glucosides
  • NF-kappa B
  • Reactive Oxygen Species
  • Vascular Cell Adhesion Molecule-1
  • cyanidin-3-O-beta-glucopyranoside
  • Angiotensin II
  • Intercellular Adhesion Molecule-1
  • Atorvastatin
  • NOS2 protein, human
  • Nitric Oxide Synthase Type II
Topics
  • Angiotensin II (physiology)
  • Anthocyanins (pharmacology)
  • Anti-Inflammatory Agents (pharmacology)
  • Atherosclerosis (drug therapy, immunology)
  • Atorvastatin (pharmacology)
  • Cell Proliferation
  • Cells, Cultured
  • Drug Evaluation, Preclinical
  • Drug Synergism
  • Enzyme Induction
  • Glucosides (pharmacology)
  • Humans
  • Intercellular Adhesion Molecule-1 (metabolism)
  • Muscle, Smooth, Vascular (drug effects, immunology)
  • Myocytes, Smooth Muscle (drug effects, immunology)
  • NF-kappa B (metabolism)
  • Nitric Oxide Synthase Type II (metabolism)
  • Oxidation-Reduction
  • Oxidative Stress
  • Reactive Oxygen Species (metabolism)
  • Signal Transduction
  • Vascular Cell Adhesion Molecule-1 (metabolism)
  • Vasculitis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: